FDA eases passage for constipation drug

March 20, 2006

The first in a new class of drugs, lubiprostone (Amitiza, Sucampo/Takeda) was approved by the Food & Drug Administration in late January for the treatment of chronic idiopathic constipation in the 33 million adults the condition is estimated to affect. It is responsible for 92,000 hospitalizations annually and is more common in women and in patients over the age of 65.